News

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 10.4% year on year to $257.7 million. Guidance for next quarter’s revenue was better than expected at $261.5 million at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 4.3% above analysts’ consensus estimates.

Shareholders of Novanta Inc. ( NASDAQ:NOVT ) will be pleased this week, given that the stock price is up 14% to US$156...

Companies In The News Are: SPG, HIMS, NOVT, HALO.

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) will be announcing earnings results this Monday after market close. Here’s what to expect.

This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings.

Novanta Inc (NOVT) reports impressive revenue and bookings growth, driven by AI and robotics, while navigating cost pressures and geopolitical uncertainties.

Novanta (NOVT) just posted first quarter results that beat earnings and revenue expectations, with sales of US$257.71 million and forward guidance above analyst estimates, marking a shift after earlier quarters of missed forecasts. See our latest analysis for Novanta. The strong first quarter beat and improved guidance appear to be feeding into momentum, with the share price up 11.8% over the past month and a year to date share price return of 26%. This is despite the 3 year total shareholder...

Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive

Moby summary of Novanta Inc.'s Q1 2026 earnings call

Novanta (NOVT) delivered earnings and revenue surprises of +3.85% and +1.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) announced better-than-expected revenue in Q1 CY2026, with sales up 10.4% year on year to $257.7 million. Guidance for next quarter’s revenue was better than expected at $261.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 4.3% above analysts’ consensus estimates.

Ouster (OUST) delivered earnings and revenue surprises of +19.36% and +6.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Novanta’s analyst story has shifted with a new consensus price target of US$150, up from US$138, now sitting against a model fair value that remains at US$157. This updated target reflects fresh views after Q4, where analysts are weighing potential upside against the risk that the company may not fully match the assumptions built into their revised models. Read on to see how these moving targets, and the narrative around them, can help you track the next phase of the Novanta story. Stay...

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.